pubmed-article:16926223 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:16926223 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
pubmed-article:16926223 | lifeskim:mentions | umls-concept:C0332174 | lld:lifeskim |
pubmed-article:16926223 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
pubmed-article:16926223 | lifeskim:mentions | umls-concept:C0671970 | lld:lifeskim |
pubmed-article:16926223 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
pubmed-article:16926223 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
pubmed-article:16926223 | pubmed:issue | 27 | lld:pubmed |
pubmed-article:16926223 | pubmed:dateCreated | 2006-9-19 | lld:pubmed |
pubmed-article:16926223 | pubmed:abstractText | The taxanes and capecitabine have synergistic antitumor activity in preclinical models. This trial was designed to determine the efficacy and tolerability of weekly paclitaxel plus capecitabine as first-line treatment for metastatic breast cancer (MBC). | lld:pubmed |
pubmed-article:16926223 | pubmed:language | eng | lld:pubmed |
pubmed-article:16926223 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16926223 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:16926223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16926223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16926223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16926223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16926223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16926223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16926223 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:16926223 | pubmed:month | Sep | lld:pubmed |
pubmed-article:16926223 | pubmed:issn | 1527-7755 | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:O'Shaughnessy... | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:AsmarLinaL | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:DeesE... | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:NeubauerMarcu... | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:BlumJoanne... | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:BoehmKristi... | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:IlegboduDesD | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:McMahonRichar... | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:ChackoAparnaA | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:DoaneLisaL | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:EthirajanSuku... | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:HopkinsJudith... | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:MertenSuzanS | lld:pubmed |
pubmed-article:16926223 | pubmed:author | pubmed-author:NegronAngelA | lld:pubmed |
pubmed-article:16926223 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:16926223 | pubmed:day | 20 | lld:pubmed |
pubmed-article:16926223 | pubmed:volume | 24 | lld:pubmed |
pubmed-article:16926223 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:16926223 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:16926223 | pubmed:pagination | 4384-90 | lld:pubmed |
pubmed-article:16926223 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:meshHeading | pubmed-meshheading:16926223... | lld:pubmed |
pubmed-article:16926223 | pubmed:year | 2006 | lld:pubmed |
pubmed-article:16926223 | pubmed:articleTitle | Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. | lld:pubmed |
pubmed-article:16926223 | pubmed:affiliation | US Oncology Research Inc, Houston, USA. joanne.blum@usoncology.com | lld:pubmed |
pubmed-article:16926223 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:16926223 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:16926223 | pubmed:publicationType | Multicenter Study | lld:pubmed |
pubmed-article:16926223 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16926223 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16926223 | lld:pubmed |